Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


Articles published in J Thorac Cardiovasc Surg

Retrieve available abstracts of 136 articles:
HTML format



Single Articles


    July 2025
  1. KHER S
    No cancer left behind: Systematic follow-up systems are essential to improve adherence to lung cancer screening.
    J Thorac Cardiovasc Surg. 2025 Jul 5:S0022-5223(25)00529.
    PubMed    


  2. INAN GA, Aksakal AK, Ayrak FB, Ergiden C, et al
    Interpreting survival comparisons in stage III non-small cell lung cancer: Performance bias and the need for subgroup-specific analysis.
    J Thorac Cardiovasc Surg. 2025 Jul 2:S0022-5223(25)00473.
    PubMed    


  3. ZERVOS M, Park BJ, Marshall MB, Wee JO, et al
    Robotic-assisted single-port system for pulmonary lobectomy: A prospective feasibility study.
    J Thorac Cardiovasc Surg. 2025;170:54-60.
    PubMed     Abstract available


    April 2025
  4. BASKIN AS, Funk EC, Francescatti AB, Sinco BR, et al
    Early Compliance with Lung Cancer Lymph Node Standard 5.8: An Analysis of 2022 and 2023 Commission on Cancer Site Reviews.
    J Thorac Cardiovasc Surg. 2025 Apr 29:S0022-5223(25)00340.
    PubMed     Abstract available


  5. EISENBERG MA, Werner R, Ries S, Hofstetter WL, et al
    Extent of Resection in Surgically Resected Stage IV Non-Small-Cell Lung Cancer: Results from Two Tertiary Referral Centers.
    J Thorac Cardiovasc Surg. 2025 Apr 23:S0022-5223(25)00327.
    PubMed     Abstract available


  6. LI H, Pezeshkian F, Xie Y, Mazzola E, et al
    Lung Cancer Recurrence after Neoadjuvant Immunotherapy.
    J Thorac Cardiovasc Surg. 2025 Apr 20:S0022-5223(25)00328.
    PubMed     Abstract available


  7. WILLIAMS JE, Jacobs RC, Savitch SL, Hollenbeck ME, et al
    Provider and Procedural Factors Associated with Guideline-Concordant Lymph Node Sampling in Lung Cancer Resection.
    J Thorac Cardiovasc Surg. 2025 Apr 17:S0022-5223(25)00304.
    PubMed     Abstract available


  8. ANTONOFF MB, Gay CM
    Timing of local consolidative pulmonary resection for oncogene-driven stage IV lung cancer.
    J Thorac Cardiovasc Surg. 2025 Apr 3:S0022-5223(25)00281.
    PubMed    


  9. MITRA S, Jang HJ, Kuncheria A, Kang SW, et al
    Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy.
    J Thorac Cardiovasc Surg. 2025;169:1082-1095.
    PubMed     Abstract available


  10. HUANG J, Tan KS, Altorki N, Antonoff M, et al
    Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacities.
    J Thorac Cardiovasc Surg. 2025;169:1100-1107.
    PubMed     Abstract available


  11. CAO H, Zhu W, Tang H, Deng C, et al
    Dissecting the clinicopathologic, genomic, and prognostic significance of anaplastic lymphoma kinase rearrangement in resected lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2025;169:1143-1152.
    PubMed     Abstract available


  12. STANIFER BP, Harris S, Nguyen SN, Vinogradsky AV, et al
    Surgical management of pleural complications in lymphangioleiomyomatosis.
    J Thorac Cardiovasc Surg. 2025;169:1133-1141.
    PubMed     Abstract available


    March 2025
  13. CURRY J, Pompili C
    Moving toward better outcomes: Time to be active before lung cancer surgery.
    J Thorac Cardiovasc Surg. 2025 Mar 11:S0022-5223(25)00123.
    PubMed    



  14. Commentator Discussion: Time to surgery in early-stage non-small cell lung cancer (NSCLC): Defining the optimal diagnosis-to-resection interval to reduce mortality.
    J Thorac Cardiovasc Surg. 2025 Mar 6:S0022-5223(25)00104.
    PubMed    


  15. CHO AR, Najafi T, Ramanakumar AV, Ferri L, et al
    The Effect of Multimodal Prehabilitation on Postoperative Outcomes in Lung Cancer Surgery.
    J Thorac Cardiovasc Surg. 2025 Mar 3:S0022-5223(25)00173.
    PubMed     Abstract available


    February 2025
  16. DENG H, Yu Z, Pan Y, Huang Y, et al
    SEGMENTECTOMY/WEDGE resection following neoadjuvant/induction immunochemotherapy in non-small cell lung cancer: Is it justified?
    J Thorac Cardiovasc Surg. 2025 Feb 7:S0022-5223(25)00008.
    PubMed    


  17. FICK CN, Dunne EG, Toumbacaris N, Tan KS, et al
    Late recurrence of completely resected stage I to IIIA lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2025;169:445-453.
    PubMed     Abstract available


  18. FICK CN, Dunne EG, Vanstraelen S, Toumbacaris N, et al
    High-risk features associated with recurrence in stage I lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2025;169:436-444.
    PubMed     Abstract available


  19. PEZESHKIAN F, Leo R, McAllister MA, Singh A, et al
    Predictors of prolonged hospital stay after segmentectomy.
    J Thorac Cardiovasc Surg. 2025;169:420-426.
    PubMed     Abstract available


    January 2025
  20. HUANG X, Zhu L, Hu J
    Surgery for lung cancer: Time waits for no one.
    J Thorac Cardiovasc Surg. 2025 Jan 31:S0022-5223(25)00005.
    PubMed    


  21. XU MM, Cerullo M
    Commentary: Missing 100% of the cancers you don't look for: pitfalls and performance of lung cancer screening efforts in a real-world setting.
    J Thorac Cardiovasc Surg. 2025 Jan 8:S0022-5223(25)00003.
    PubMed    


  22. THERRIAULT CS, Kim AW
    Commentary: The Ticking Lung Cancer Clock.
    J Thorac Cardiovasc Surg. 2025 Jan 8:S0022-5223(25)00004.
    PubMed    


  23. BOTT MJ, Toumbacaris N, Tan KS, Husta BC, et al
    Characterizing a learning curve for robotic-assisted bronchoscopy: Analysis of skills acquisition in a high-volume academic center.
    J Thorac Cardiovasc Surg. 2025;169:269-278.
    PubMed     Abstract available


    December 2024
  24. FUKUI M, Suzuki K
    Reply: Prognostic significance of preoperative exercise tolerance in patients with early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2024 Dec 27:S0022-5223(24)01133.
    PubMed    


  25. KOYLU B, Guven DC
    Controversial influence of adjuvant immunotherapy in survival outcomes for patients with non-small cell lung cancer with major/complete pathologic response.
    J Thorac Cardiovasc Surg. 2024 Dec 26:S0022-5223(24)01186.
    PubMed    


  26. DE PERROT M
    Reply: The pulmonary sulcus phenomenon in lung cancer invading the chest wall.
    J Thorac Cardiovasc Surg. 2024 Dec 23:S0022-5223(24)01095.
    PubMed    


  27. ALTORKI N, Wang X, Damman B, Mentlick J, et al
    Corrigendum to: Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance)" [The Journal of Thoracic and Cardiovascular Surgery Volume 167, Issue 1, January 202
    J Thorac Cardiovasc Surg. 2024 Dec 20:S0022-5223(24)01142.
    PubMed    


  28. PARIKH MJ, Chai LF, Russo MG, Tompkins AK, et al
    Dismal Adherence to Lung Cancer Screening in a Diverse Urban Population.
    J Thorac Cardiovasc Surg. 2024 Dec 13:S0022-5223(24)01136.
    PubMed     Abstract available


  29. ZOLFAGHARI EJ, Ayoade O, Antonoff MB
    Barriers to fitness: Disparities in preoperative exercise access for patients with lung cancer.
    J Thorac Cardiovasc Surg. 2024 Dec 13:S0022-5223(24)01096.
    PubMed    


  30. TUPPER HI, Sarovar V, Banks KC, Schmittdiel JA, et al
    Time to Surgery in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Defining the Optimal Diagnosis-to-Resection Interval to Reduce Mortality.
    J Thorac Cardiovasc Surg. 2024 Dec 12:S0022-5223(24)01125.
    PubMed     Abstract available


  31. ZHU W, Han H, Ma Z, Cao H, et al
    Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features.
    J Thorac Cardiovasc Surg. 2024;168:1525-1537.
    PubMed     Abstract available


    November 2024
  32. ZHAO ZR, Yan WP, Yu XY, Zhang JB, et al
    Adjuvant Immunotherapy Does Not Improve Survival in Non-small Cell Lung Cancer with Major/Complete Pathological Response after Induction Immunotherapy.
    J Thorac Cardiovasc Surg. 2024 Nov 29:S0022-5223(24)01109.
    PubMed     Abstract available


  33. FERRARIS VA
    Commentary: On 'Gender, Race, and Ethnicity in Lung Cancer Clinical Trial Participation'.
    J Thorac Cardiovasc Surg. 2024 Nov 10:S0022-5223(24)01029.
    PubMed    


  34. UDELSMAN BV, Bedrosian CK, Kawaguchi ES, Ding L, et al
    Living on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff.
    J Thorac Cardiovasc Surg. 2024 Nov 7:S0022-5223(24)01021.
    PubMed     Abstract available



  35. Discussion to: Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024;168:1360-1361.
    PubMed    



  36. Discussion to: Should sampling of 3 N2 stations be a quality metric for curative resection of stage I lung cancer?
    J Thorac Cardiovasc Surg. 2024;168:1346-1348.
    PubMed    


  37. WANG S, Meng F, Chen P, Lv Y, et al
    Cell-free DNA assay for malignancy classification of high-risk lung nodules.
    J Thorac Cardiovasc Surg. 2024;168:e140-e175.
    PubMed     Abstract available


    October 2024
  38. GALVAING G, Drevet G, Tricard J, Gregoire J, et al
    Lung cancer invading the chest wall: The role of site of chest wall invasion.
    J Thorac Cardiovasc Surg. 2024 Oct 17:S0022-5223(24)00826.
    PubMed    


  39. RABINOVICH EP, Martin LW
    Getting Patients to Adjuvant Therapy after Lung Cancer Resection: ERAS Protocols and Return to Intended Oncologic Therapy.
    J Thorac Cardiovasc Surg. 2024 Oct 10:S0022-5223(24)00916.
    PubMed    


  40. HUTCHINGS H, Boyajian H, Okereke I
    Reply: Achieving environmental justice will reduce lung cancer health disparities.
    J Thorac Cardiovasc Surg. 2024 Oct 9:S0022-5223(24)00766.
    PubMed    


  41. YUAN W, Huang R, Yang Z
    Will salvage surgery lead to a paradigm shift in the treatment of stage IV lung cancer?
    J Thorac Cardiovasc Surg. 2024 Oct 4:S0022-5223(24)00808.
    PubMed    


  42. LEE JM
    Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing.
    J Thorac Cardiovasc Surg. 2024;168:1281-1288.
    PubMed    


  43. YANG Z, Wang S, Yang H, Jiang Y, et al
    Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    J Thorac Cardiovasc Surg. 2024;168:1245-1258.
    PubMed     Abstract available


    September 2024
  44. KANUPARTHY M, Kanuparthy S, Harris DD, Broadwin M, et al
    Gender, Race, and Ethnicity in Lung Cancer Clinical Trial Participation: Analysis of 253,845 Patients From 2002 - 2021.
    J Thorac Cardiovasc Surg. 2024 Sep 28:S0022-5223(24)00893.
    PubMed     Abstract available


  45. FERRARI-LIGHT D, Merritt RE, D'Souza D, Ferguson MK, et al
    Evaluating ChatGPT as a Patient Resource for Frequently Asked Questions about Lung Cancer Surgery - A Pilot Study.
    J Thorac Cardiovasc Surg. 2024 Sep 24:S0022-5223(24)00837.
    PubMed     Abstract available


  46. BRUNELLI A, Antonoff MB, Petersen RH, Stiles BM, et al
    Surgeon preferences for self-treatment in locally advanced non-small cell lung cancer: Would we practice what we preach?
    J Thorac Cardiovasc Surg. 2024 Sep 19:S0022-5223(24)00526.
    PubMed    


  47. ADACHI H, Ito H, Nagashima T, Isaka T, et al
    Mediastinal lymph node dissection in segmentectomy for peripheral c-stage IA (
    J Thorac Cardiovasc Surg. 2024 Sep 9:S0022-5223(24)00786.
    PubMed     Abstract available


  48. CHEN H, Kim AW, Hsin M, Shrager JB, et al
    The 2023 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Management of subsolid lung nodules.
    J Thorac Cardiovasc Surg. 2024;168:631-647.
    PubMed     Abstract available



  49. Discussion to: Oncological characteristics of EGFR-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance.
    J Thorac Cardiovasc Surg. 2024;168:697-698.
    PubMed    



  50. Discussion to: Digital spatial profiling to predict recurrence in grade 3 stage I lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2024;168:658-659.
    PubMed    


  51. HATTORI A, Matsunaga T, Fukui M, Tomita H, et al
    Oncological characteristics of epidermal growth factor receptor-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance.
    J Thorac Cardiovasc Surg. 2024;168:685-696.
    PubMed     Abstract available


  52. CHANG SH, Mezzano-Robinson V, Zhou H, Moreira A, et al
    Digital spatial profiling to predict recurrence in grade 3 stage I lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2024;168:648-657.
    PubMed     Abstract available


    August 2024
  53. HOODA Z, Antonoff MB
    Air-Quality variability highlights disparities in lung cancer.
    J Thorac Cardiovasc Surg. 2024 Aug 24:S0022-5223(24)00674.
    PubMed    


  54. CHU NQ, Tan KS, Dycoco J, Adusumilli PS, et al
    Determinants of successful minimally invasive surgery (MIS) for resectable non-small cell lung cancer (NSCLC) after neoadjuvant therapy.
    J Thorac Cardiovasc Surg. 2024 Aug 19:S0022-5223(24)00696.
    PubMed     Abstract available



  55. Commentator Discussion: Influence of air quality on lung cancer in people who have never smoked.
    J Thorac Cardiovasc Surg. 2024 Aug 12:S0022-5223(24)00650.
    PubMed    


    July 2024

  56. Commentator Discussion: Preoperatively predicting survival outcome for clinical stage IA pure-solid non-small cell lung cancer by radiomics-based machine learning.
    J Thorac Cardiovasc Surg. 2024 Jul 30:S0022-5223(24)00556.
    PubMed    


  57. LI T, Zhang Y, Fu F, Chen H, et al
    The Evolution of the Treatment of Non-small Cell Lung Cancer: A Shift in Surgical Paradigm to A More Individualized Approach.
    J Thorac Cardiovasc Surg. 2024 Jul 25:S0022-5223(24)00655.
    PubMed    


  58. SMITH R JR, Gee KN, Kalvapudi S, Pachimatla A, et al
    Sex-based Differences in the Lung Immune Microenvironment Are Associated with an Increased Risk of Lung Cancer in Women.
    J Thorac Cardiovasc Surg. 2024 Jul 15:S0022-5223(24)00617.
    PubMed     Abstract available


  59. WATKINS AA, Rizvi TZ, Lopez E, Shehata D, et al
    Trends and Comparative Outcomes Between Operative Approaches for Segmentectomy in Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Jul 11:S0022-5223(24)00605.
    PubMed     Abstract available


  60. LIN Y
    Accurate predictor of occult mediastinal nodal metastasis in stage I lower-lobe non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Jul 5:S0022-5223(24)00381.
    PubMed    


  61. TSUBOKAWA N, Mimae T, Saeki A, Miyata Y, et al
    Feasibility and Comparative Prognosis of Segmentectomy vs. Lobectomy in Centrally Located Small and Solid Dominant cN0 Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Jul 3:S0022-5223(24)00538.
    PubMed     Abstract available


  62. MACBETH F, Williams N, Ahmad I, Treasure T, et al
    Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy.
    J Thorac Cardiovasc Surg. 2024;168:e10-e11.
    PubMed    


  63. ANTONOFF MB, Kui N, Sun R, Deboever N, et al
    Factors associated with receipt of pulmonary metastasectomy in patients with lung-limited metastatic colorectal cancer: Disparities in care and impact on overall survival.
    J Thorac Cardiovasc Surg. 2024;168:263-271.
    PubMed     Abstract available


    June 2024
  64. HUTCHINGS H, Wang A, Grady S, Popoff A, et al
    Influence of Air Quality on Lung Cancer in People Who Have Never Smoked.
    J Thorac Cardiovasc Surg. 2024 Jun 25:S0022-5223(24)00536.
    PubMed     Abstract available


  65. BOTT MJ
    Commentary: Cracking the Code: Deciphering Predictors of Treatment Response in Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Jun 13:S0022-5223(24)00527.
    PubMed    



  66. Discussion to: Computational risk model for predicting 2-year malignancy of pulmonary nodules using demographic and radiographic characteristics.
    J Thorac Cardiovasc Surg. 2024;167:1925-1926.
    PubMed    


  67. SARNAIK KS, Linden PA, Gasnick A, Bassiri A, et al
    Computational risk model for predicting 2-year malignancy of pulmonary nodules using demographic and radiographic characteristics.
    J Thorac Cardiovasc Surg. 2024;167:1910-1924.
    PubMed     Abstract available


    May 2024
  68. YAN H, Niimi T, Matsunaga T, Fukui M, et al
    Preoperatively Predicting Survival Outcome for Clinical Stage IA Pure-Solid Non-Small Cell Lung Cancer by Radiomics-based Machine Learning.
    J Thorac Cardiovasc Surg. 2024 May 22:S0022-5223(24)00441.
    PubMed     Abstract available


  69. XU L, Si H, Zhuang F, Li C, et al
    Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 May 17:S0022-5223(24)00437.
    PubMed     Abstract available


  70. HSU DS, Kneuertz PJ
    Commentary: "HIIT"ing the Jackpot with Prehabilitation before Minimally Invasive Lung Cancer Surgery.
    J Thorac Cardiovasc Surg. 2024 May 3:S0022-5223(24)00374.
    PubMed    


  71. JONES DR, Bueno R, Harpole DH Jr, Vaporciyan AA, et al
    Thoracic Surgical Oncology Group: An American Association for Thoracic Surgery Clinical Trials Initiative.
    J Thorac Cardiovasc Surg. 2024;167:1584-1588.
    PubMed    


    April 2024
  72. ZHOU N, Ripley-Gonzalez JW, Zhang W, Xie K, et al
    Preoperative Exercise Training Decreases Complications of Minimally Invasive Lung Cancer Surgery- A Randomized Controlled Trial.
    J Thorac Cardiovasc Surg. 2024 Apr 11:S0022-5223(24)00296.
    PubMed     Abstract available


  73. ODEH AM, Perez-Tamayo RA, Abdelsattar ZM
    A wedge is still better than stereotactic body radiation therapy in the national cancer database.
    J Thorac Cardiovasc Surg. 2024;167:e100-e101.
    PubMed    


  74. KIM AT, Ding L, Lee HB, Ashbrook MJ, et al
    Longer hospitalizations, more complications, and greater readmissions for patients with comorbid psychiatric disorders undergoing pulmonary lobectomy.
    J Thorac Cardiovasc Surg. 2024;167:1502-1511.
    PubMed     Abstract available


    March 2024
  75. RUSCH VW
    Commentary: "Real world" neoadjuvant immunochemotherapy for lung cancer:Additional data but still many questions.
    J Thorac Cardiovasc Surg. 2024 Mar 14:S0022-5223(24)00209.
    PubMed    


  76. KRISTENSON K, Hedman K
    Percent predicted peak oxygen uptake is superior to weight-indexed peak oxygen uptake in risk stratification before lung cancer lobectomy.
    J Thorac Cardiovasc Surg. 2024 Mar 5:S0022-5223(24)00187.
    PubMed     Abstract available



  77. Discussion to: AATS 2023: Empiric flap coverage for the pneumonectomy stump: How protective is it? A single-institution cohort study.
    J Thorac Cardiovasc Surg. 2024;167:859-860.
    PubMed    



  78. Discussion to: Extent of surgical resection for radiologically subsolid T1N0 invasive lung adenocarcinoma: When is a wedge resection acceptable?
    J Thorac Cardiovasc Surg. 2024;167:810-811.
    PubMed    


  79. STEIMER D, Coughlin JM, Yates E, Xie Y, et al
    Empiric flap coverage for the pneumonectomy stump: How protective is it? A single-institution cohort study.
    J Thorac Cardiovasc Surg. 2024;167:849-858.
    PubMed     Abstract available


  80. SACHDEVA UM
    Commentary: The genes stand alone: Genetic risk factors predict early pulmonary recurrence of colorectal carcinoma metastases.
    J Thorac Cardiovasc Surg. 2024;167:820-821.
    PubMed    


  81. DEBOEVER N, Bayley EM, Eisenberg MA, Hofstetter WL, et al
    Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy.
    J Thorac Cardiovasc Surg. 2024;167:814-819.
    PubMed     Abstract available


  82. ZHANG C, Pan Y, Li H, Zhang Y, et al
    Extent of surgical resection for radiologically subsolid T1N0 invasive lung adenocarcinoma: When is a wedge resection acceptable?
    J Thorac Cardiovasc Surg. 2024;167:797-809.
    PubMed     Abstract available


    February 2024
  83. COOPER A, Chaft JE, Bott MJ
    Induction Therapy for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 12:S0022-5223(24)00160.
    PubMed    



  84. Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 10:S0022-5223(24)00022.
    PubMed    


  85. KOREVAAR DA, Annema JT
    Targeted versus systematic nodal staging in early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 8:S0022-5223(24)00004.
    PubMed    


  86. CALL S, Reig-Oussedik N, Obiols C, Sanz-Santos J, et al
    Video-assisted mediastinoscopic lymphadenectomy (VAMLA): mature results for staging non-small cell lung cancer with normal mediastinum.
    J Thorac Cardiovasc Surg. 2024 Feb 2:S0022-5223(24)00098.
    PubMed     Abstract available


  87. ZHANG X, Tsauo J, Tian P, Zhao L, et al
    Randomized comparison of the four-hook anchor device and hook-wire use for the preoperative localization of pulmonary nodules.
    J Thorac Cardiovasc Surg. 2024;167:498-507.
    PubMed     Abstract available


    January 2024

  88. Discussion to: National enrollment of lung cancer clinical trials is disproportionate based on race and health care access.
    J Thorac Cardiovasc Surg. 2024 Jan 27:S0022-5223(23)01209.
    PubMed    


  89. MARTIN TK, Dinerman A, Sudhaman S, Budde G, et al
    Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Jan 18:S0022-5223(24)00075.
    PubMed     Abstract available


  90. FUKUI M, Matsunaga T, Hattori A, Takamochi K, et al
    Prognostic significance of preoperative exercise tolerance in patients with early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2024 Jan 11:S0022-5223(24)00006.
    PubMed     Abstract available


  91. LIN N, Berry MF
    Commentary: Re-consult surgery for lung cancer patients? The role of resection after initial non-operative therapy.
    J Thorac Cardiovasc Surg. 2024 Jan 9:S0022-5223(24)00007.
    PubMed    


  92. TOHMASI S, Puri V
    Commentary: Segmentectomy versus lobectomy: Are the findings of the JCOG 0802 and CALGB 140503 trials generalizable to the US population?
    J Thorac Cardiovasc Surg. 2024;167:365-366.
    PubMed    


  93. POTTER AL, Kim J, McCarthy ML, Senthil P, et al
    Segmentectomy versus lobectomy in the United States: Outcomes after resection for first primary lung cancer and treatment patterns for second primary lung cancers.
    J Thorac Cardiovasc Surg. 2024;167:350-364.
    PubMed     Abstract available


    December 2023

  94. Discussion to: Preoperative predictors of spread through air spaces in lung cancer.
    J Thorac Cardiovasc Surg. 2023 Dec 27:S0022-5223(23)01119.
    PubMed    



  95. Discussion to: Lung resection after initial nonoperative treatment for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Dec 27:S0022-5223(23)01129.
    PubMed    


  96. KWAK M, Bassiri A, Jiang B, Sinopoli J, et al
    National enrollment of lung cancer clinical trials is disproportionate based on race and health care access.
    J Thorac Cardiovasc Surg. 2023 Dec 18:S0022-5223(23)01199.
    PubMed     Abstract available


  97. SAKOWITZ S, Bakhtiyar SS, Curry J, Ali K, et al
    Association of Neighborhood Socioeconomic Disadvantage with Utilization of Minimally Invasive Resection for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Dec 13:S0022-5223(23)01195.
    PubMed     Abstract available


  98. DONINGTON J, Hu X, Zhang S, Song Y, et al
    Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy.
    J Thorac Cardiovasc Surg. 2023 Dec 11:S0022-5223(23)01193.
    PubMed     Abstract available


  99. SERVAIS EL
    Commentary: Utilization and equity in lung cancer screening: time to abandon the one-size-fits-all approach?
    J Thorac Cardiovasc Surg. 2023 Dec 4:S0022-5223(23)01122.
    PubMed    



  100. Discussion to: Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management.
    J Thorac Cardiovasc Surg. 2023;166:1488-1489.
    PubMed    


  101. MCLAUGHLIN K, Tan KS, Dycoco J, Chen MF, et al
    Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management.
    J Thorac Cardiovasc Surg. 2023;166:1477-1487.
    PubMed     Abstract available


  102. CAO H, Ma Z, Li Y, Zhang Y, et al
    Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
    J Thorac Cardiovasc Surg. 2023;166:e479-e499.
    PubMed     Abstract available


  103. SARKARIA IS, Martin LW, Rice DC, Blackmon SH, et al
    Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial.
    J Thorac Cardiovasc Surg. 2023;166:e468-e478.
    PubMed     Abstract available


    November 2023
  104. DUNNE EG, Fick CN, Tan KS, Toumbacaris N, et al
    Lung Resection After Initial Nonoperative Treatment for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 30:S0022-5223(23)01116.
    PubMed     Abstract available



  105. Discussion to: Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 28:S0022-5223(23)00992.
    PubMed    


  106. TASNIM S, Raja S, Mukhopadhyay S, Blackstone EH, et al
    Preoperative Predictors of Spread Through Air Spaces (STAS) in Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 23:S0022-5223(23)01106.
    PubMed     Abstract available


  107. MANIWA T, Okami J, Miyoshi T, Wakabayashi M, et al
    Lymph node dissection in small peripheral lung cancer: supplemental analysis of JCOG0802/WJOG4607L.
    J Thorac Cardiovasc Surg. 2023 Nov 22:S0022-5223(23)01099.
    PubMed     Abstract available


  108. DYAS AR, Bronsert MR, Stuart CM, Thomas MB, et al
    Analyzing the Impact of the COVID-19 Pandemic on Initial Oncologic Presentation and Treatment of Non-Small Cell Lung Cancer in the United States.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01098.
    PubMed     Abstract available


  109. SULLIVAN KA, Farrokhyar F, Patel YS, Liberman M, et al
    Preoperative Mediastinal Staging in Early-Stage Lung Cancer: Targeted Nodal Sampling is Not Inferior to Systematic Nodal Sampling.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01096.
    PubMed     Abstract available



  110. Discussion to: Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)00979.
    PubMed    



  111. Discussion to AATS 2023: Exposure to Agent Orange is associated with increased recurrence after surgical treatment of stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 9:S0022-5223(23)00904.
    PubMed    


  112. AL-THANI S, Nasar A, Villena-Vargas J, Chow O, et al
    Should Sampling of Three N2 Stations be a Quality Metric for Curative Resection of Stage I Lung Cancer?
    J Thorac Cardiovasc Surg. 2023 Nov 3:S0022-5223(23)01015.
    PubMed     Abstract available


  113. SEPESI B, Mehran R, Spicer J, Cascone T, et al
    Neostar Trial and The Current Status of Neoadjuvant Therapy in Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 1:S0022-5223(23)01012.
    PubMed    


    October 2023

  114. Discussion to: Quality improvement mechanisms to improve lymph node staging for lung cancer: Trends from a statewide database.
    J Thorac Cardiovasc Surg. 2023 Oct 20:S0022-5223(23)00865.
    PubMed    



  115. Discussion to: Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery.
    J Thorac Cardiovasc Surg. 2023 Oct 20:S0022-5223(23)00867.
    PubMed    


  116. REDDY RM
    Commentary: Neoadjuvant Immunotherapy followed by Lung Cancer Resection: Is the Future Already Here?
    J Thorac Cardiovasc Surg. 2023 Oct 18:S0022-5223(23)00980.
    PubMed    


  117. POTTER AL, Senthil P, Srinivasan D, Raman V, et al
    Persistent Racial and Sex-based Disparities in Lung Cancer Screening Eligibility.
    J Thorac Cardiovasc Surg. 2023 Oct 18:S0022-5223(23)00981.
    PubMed     Abstract available


  118. WOLF AS
    Commentary: Nothing is free: Surgeons' and radiation oncologists' biases about treating early stage lung cancer in healthy patients.
    J Thorac Cardiovasc Surg. 2023 Oct 17:S0022-5223(23)00986.
    PubMed    


  119. KAMTAM DN, Shrager JB
    We should be considering lung cancer screening for never-smoking Asian-American females.
    J Thorac Cardiovasc Surg. 2023 Oct 14:S0022-5223(23)00976.
    PubMed    


  120. FELDMAN H, Sepesi B, Leung CH, Lin H, et al
    Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Oct 8:S0022-5223(23)00900.
    PubMed     Abstract available


  121. YOSHINO I, Moriya Y, Suzuki K, Wakabayashi M, et al
    Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections.
    J Thorac Cardiovasc Surg. 2023;166:1222-1231.
    PubMed     Abstract available


  122. STEIMER D, Ugalde Figueroa P
    Commentary: Sublobar resection for ground-glass opacity: Is less really more?
    J Thorac Cardiovasc Surg. 2023;166:1232-1233.
    PubMed    


    September 2023

  123. Discussion to: Perspectives, risk factors, and coping mechanisms in patients with self-reported financial burden following lung cancer surgery.
    J Thorac Cardiovasc Surg. 2023 Sep 30:S0022-5223(23)00783.
    PubMed    


  124. ANTONOFF MB, Deboever N, Werner R, Altan M, et al
    Surgery for Oligometastatic Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 29:S0022-5223(23)00874.
    PubMed     Abstract available


  125. ELBAHRAWY MM, Kamel MK, Rodriguez-Quintero JH, Vimolratana M, et al
    Association of Socioeconomic Factors with the Receipt of Neoadjuvant Therapy for Patients with Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 21:S0022-5223(23)00857.
    PubMed     Abstract available


  126. KUMAR A, Srinivasan D, Potter A, Mathey-Andrews C, et al
    Induction Chemoimmunotherapy with Surgery versus Concurrent Chemoradiation followed by Immunotherapy for Stage III-N2 Non-small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 16:S0022-5223(23)00853.
    PubMed     Abstract available


  127. POTTER AL, Rosenstein AL, Kandala K, Venkateswaran S, et al
    Shortage of Thoracic Surgeons in the United States: Implications for Treatment and Survival for Stage I Lung Cancer Patients.
    J Thorac Cardiovasc Surg. 2023 Sep 14:S0022-5223(23)00796.
    PubMed     Abstract available


  128. SUBRAMANIAN MP, Eaton DB Jr, Labilles UL, Heiden BT, et al
    Exposure to Agent Orange is Associated with Increased Recurrence after Surgical Treatment of Stage I Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 12:S0022-5223(23)00788.
    PubMed     Abstract available


  129. EISENBERG MA, Deboever N, Mills AC, Egyud MR, et al
    Impact of Travel Distance on Receipt of Indicated Adjuvant Therapy in Resected Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 9:S0022-5223(23)00765.
    PubMed     Abstract available


    August 2023
  130. ALTORKI NK, Chow OS
    Cancer and Leukemia Group B 140503: Is it time to turn the page on Lung Cancer Study Group 821?
    J Thorac Cardiovasc Surg. 2023 Aug 18:S0022-5223(23)00725.
    PubMed    


    March 2023
  131. D'AMICO TA
    Japanese Oncology Group 0802: Another giant leap.
    J Thorac Cardiovasc Surg. 2023;165:873-875.
    PubMed    


  132. CHEN Z, Bernards N, Gregor A, Vannelli C, et al
    Anatomic evaluation of Pancoast tumors using three-dimensional models for surgical strategy development.
    J Thorac Cardiovasc Surg. 2023;165:842-852.
    PubMed     Abstract available


  133. INRA ML, Wasserman GA, Karp J, Cohen S, et al
    Improvement in postoperative lung function in patients with moderate to severe airway obstruction after robotic-assisted thoracoscopic tracheobronchoplasty.
    J Thorac Cardiovasc Surg. 2023;165:876-885.
    PubMed     Abstract available


  134. ZHOU D, Gao Y, Wang H, Xin H, et al
    Prevalence and anatomical characteristics of subsuperior segment in lung lower lobe.
    J Thorac Cardiovasc Surg. 2023;165:864-872.
    PubMed     Abstract available


  135. PEREZ HOLGUIN RA, Olecki EJ, Wong WG, Stahl KA, et al
    Outcomes after sublobar resection versus lobectomy in non-small cell carcinoma in situ.
    J Thorac Cardiovasc Surg. 2023;165:853-861.
    PubMed     Abstract available


  136. BERTOLACCINI L, Spaggiari L
    Commentary: The sublobar resections and the difference between a conjecture and a theorem.
    J Thorac Cardiovasc Surg. 2023;165:862-863.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.